Fleebs-Logo
Details werden geladen...

Hepatitis D - NIDDK

Overview of hepatitis D, an infection that only occurs with hepatitis B and causes liver inflammation and damage. Hepatitis D can be acute or chronic.

Videos

Why Should I Join a Clinical Trial?
1 Minuten 50 Sekunden

Why Should I Join a Clinical Trial?

Ähnliche Seiten

https://www.niddk.nih.gov/health-information/liver-disease

Liver Disease - NIDDK

https://www.niddk.nih.gov/health-information/liver-disease
https://www.manilatimes.net/2026/04/15/tmt-newswire/globenewswire/aligos-therapeutics-announces-first-interim-analysis-results-from-the-phase-2-b-supreme-study-of-pevifoscorvir-sodium-in-participants-with-chronic-hepatitis-b-virus-infection-and-grant-of-fda-fast-track-designation/2320439

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Tr...

https://www.manilatimes.net/2026/04/15/tmt-newswire/globenewswire/aligos-therapeutics-announces-first-interim-analysis-results-from-the-phase-2-b-supreme-study-of-pevifoscorvir-sodium-in-participants-with-chronic-hepatitis-b-virus-infection-and-grant-of-fda-fast-track-designation/2320439
https://www.scientificamerican.com/article/what-you-need-to-know-about-hantavirus-the-infection-at-the-center-of-a-deadly-cruise-ship-outbreak/

What you need to know about hantavirus, the infection at the center of a deadly cruise ship outbreak | Scientific American

https://www.scientificamerican.com/article/what-you-need-to-know-about-hantavirus-the-infection-at-the-center-of-a-deadly-cruise-ship-outbreak/
https://www.manilatimes.net/2026/03/17/tmt-newswire/globenewswire/gyre-therapeutics-announces-chinas-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment/2301622

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment | The Manila Times

https://www.manilatimes.net/2026/03/17/tmt-newswire/globenewswire/gyre-therapeutics-announces-chinas-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment/2301622
https://www.sciencedaily.com/releases/2026/04/260405003949.htm

A drug already in trials may finally stop hepatitis E | ScienceDaily

https://www.sciencedaily.com/releases/2026/04/260405003949.htm
https://www.sciencedaily.com/releases/2026/03/260323005545.htm

A promising fatty liver treatment may raise cancer risk | ScienceDaily

https://www.sciencedaily.com/releases/2026/03/260323005545.htm